Repertoire Immune Medicines Secures $189M in Series B Funding to Accelerate Next-Generation Immune Therapies

Repertoire Immune Medicines is thrilled to announce a major funding milestone with the successful raise of $189,000,000, a strategic investment that will accelerate breakthroughs in immune-based therapies. As a pioneering biotechnology company, Repertoire is dedicated to leveraging the power of the human T cell repertoire to combat cancer, neutralize pathogens, and fine-tune immune responses in autoimmune diseases. At the heart of this innovation is their proprietary DECODE™ platform, a transformative technology that offers a comprehensive dissection of T-cell receptor interactions with antigens. By uniquely mapping the entire immune synapse—including detailed T-cell receptor-epitope pairs, HLA context, and T cell phenotypes—DECODE™ enables the discovery and development of novel therapeutic approaches that have the potential to redefine treatment paradigms across multiple disease areas. This significant capital infusion will empower the company to further refine and expand its DECODE™ platform, driving forward a robust pipeline of therapies targeting a spectrum of health challenges from autoimmune disorders and infectious diseases to various forms of cancer. The funding will also support vital clinical research, enhance technological capabilities, and foster collaborative partnerships, ultimately ensuring that pioneering treatments move swiftly from laboratory to patient care. With operational hubs in Cambridge, Massachusetts and Zurich, Repertoire Immune Medicines is poised to take its cutting-edge science to new heights, solidifying its role as a leader in the quest for innovative, immune-based medical solutions. For more information about Repertoire’s groundbreaking work and future endeavors, please visit www.repertoire.com.